-
Je něco špatně v tomto záznamu ?
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
KW. Pratz, P. Panayiotidis, C. Recher, X. Wei, BA. Jonas, P. Montesinos, V. Ivanov, AC. Schuh, CD. DiNardo, J. Novak, V. Pejsa, D. Stevens, SP. Yeh, I. Kim, M. Turgut, N. Fracchiolla, K. Yamamoto, Y. Ofran, AH. Wei, CN. Bui, K. Benjamin, R....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Freely Accessible Science Journals
od 2011-01-28
Nature Open Access
od 2011-01-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
Springer Nature OA/Free Journals
od 2011-01-01
- MeSH
- akutní myeloidní leukemie * farmakoterapie etiologie MeSH
- bicyklické sloučeniny heterocyklické MeSH
- cytarabin terapeutické užití MeSH
- kvalita života * MeSH
- lidé MeSH
- protokoly protinádorové kombinované chemoterapie škodlivé účinky MeSH
- sulfonamidy MeSH
- únava etiologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.
AbbVie Inc North Chicago IL USA
Abramson Cancer Center University of Pennsylvania Philadelphia PA USA
Almazov National Medical Research Center Saint Petersburg Russian Federation
Australian Center for Blood Diseases The Alfred Hospital and Monash University Melbourne Australia
Department of Hematology and Cell Therapy Aichi Cancer Center Nagoya Japan
Department of Internal Medicine China Medical University Hospital Taichung Taiwan
Genentech Inc South San Francisco CA USA
Hematology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
Hospital Universitario y Politécnico La Fe Valencia Spain
National and Kapodistrian University of Athens Medical School Laiko General Hospital Athens Greece
Norton Cancer Institute Louisville KY USA
Princess Margaret Cancer Centre and University of Toronto Toronto ON Canada
Seoul National University Hospital Seoul Republic of Korea
The Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou China
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018742
- 003
- CZ-PrNML
- 005
- 20220804135049.0
- 007
- ta
- 008
- 220720s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41408-022-00668-8 $2 doi
- 035 __
- $a (PubMed)35443742
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Pratz, Keith W $u Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. keith.pratz@pennmedicine.upenn.edu $1 https://orcid.org/0000000212848266
- 245 10
- $a Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia / $c KW. Pratz, P. Panayiotidis, C. Recher, X. Wei, BA. Jonas, P. Montesinos, V. Ivanov, AC. Schuh, CD. DiNardo, J. Novak, V. Pejsa, D. Stevens, SP. Yeh, I. Kim, M. Turgut, N. Fracchiolla, K. Yamamoto, Y. Ofran, AH. Wei, CN. Bui, K. Benjamin, R. Kamalakar, J. Potluri, W. Mendes, J. Devine, W. Fiedler
- 520 9_
- $a Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
- 650 _2
- $a bicyklické sloučeniny heterocyklické $7 D019086
- 650 _2
- $a cytarabin $x terapeutické užití $7 D003561
- 650 _2
- $a únava $x etiologie $7 D005221
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a akutní myeloidní leukemie $x farmakoterapie $x etiologie $7 D015470
- 650 12
- $a kvalita života $7 D011788
- 650 _2
- $a sulfonamidy $7 D013449
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Panayiotidis, Panayiotis $u National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece
- 700 1_
- $a Recher, Christian $u Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France $1 https://orcid.org/0000000233324525
- 700 1_
- $a Wei, Xudong $u The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, China
- 700 1_
- $a Jonas, Brian A $u Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA $1 https://orcid.org/0000000249215809
- 700 1_
- $a Montesinos, Pau $u Hospital Universitario y Politécnico La Fe, Valencia, Spain $1 https://orcid.org/0000000232755593
- 700 1_
- $a Ivanov, Vladimir $u Almazov National Medical Research Center, Saint Petersburg, Russian Federation
- 700 1_
- $a Schuh, Andre C $u Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
- 700 1_
- $a DiNardo, Courtney D $u Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA $1 https://orcid.org/0000000190030390
- 700 1_
- $a Novak, Jan $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Pejsa, Vlatko $u Department of Hematology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia
- 700 1_
- $a Stevens, Don $u Norton Cancer Institute, Louisville, KY, USA
- 700 1_
- $a Yeh, Su-Peng $u Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
- 700 1_
- $a Kim, Inho $u Seoul National University Hospital, Seoul, Republic of Korea
- 700 1_
- $a Turgut, Mehmet $u Department of Internal Medicine, Division of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey
- 700 1_
- $a Fracchiolla, Nicola $u Hematology Unit, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy
- 700 1_
- $a Yamamoto, Kazuhito $u Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan $1 https://orcid.org/0000000285888955
- 700 1_
- $a Ofran, Yishai $u Department of Hematology, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
- 700 1_
- $a Wei, Andrew H $u Australian Center for Blood Diseases, The Alfred Hospital and Monash University, Melbourne, Australia
- 700 1_
- $a Bui, Cat N $u AbbVie Inc., North Chicago, IL, USA
- 700 1_
- $a Benjamin, Katy $u AbbVie Inc., North Chicago, IL, USA
- 700 1_
- $a Kamalakar, Rajesh $u AbbVie Inc., North Chicago, IL, USA
- 700 1_
- $a Potluri, Jalaja $u AbbVie Inc., North Chicago, IL, USA
- 700 1_
- $a Mendes, Wellington $u AbbVie Inc., North Chicago, IL, USA $1 https://orcid.org/0000000207338456
- 700 1_
- $a Devine, Jacob $u Genentech Inc., South San Francisco, CA, USA
- 700 1_
- $a Fiedler, Walter $u Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 773 0_
- $w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 12, č. 4 (2022), s. 71
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35443742 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135043 $b ABA008
- 999 __
- $a ok $b bmc $g 1822385 $s 1169985
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 12 $c 4 $d 71 $e 20220420 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
- LZP __
- $a Pubmed-20220720
